Evolving Strategies in Hepatitis C: Cure, Prevention, and Beyond

Nov 10 2025
Convention Center: Ballroom B, Level 3
11:00 AM - 12:30 PM

World Class Speakers

AB
Abstract Presenter

Andrea D Branch, PhD

Icahn School of Medicine at Mount Sinai (ISMMS)
Harrys A Torres, MD, FAASLD
Abstract Presenter

Harrys A Torres, MD, FAASLD

The University of Texas MD Anderson Cancer Center
AB
Moderator

Andrea D Branch, PhD

Icahn School of Medicine at Mount Sinai (ISMMS)
Harrys A Torres, MD, FAASLD
Moderator

Harrys A Torres, MD, FAASLD

The University of Texas MD Anderson Cancer Center

Description

This session highlights cutting-edge research in Hepatitis C treatment, including next-generation antivirals, optimized therapy durations, and strategies for long-term patient outcomes post-cure. Presenters will share findings from clinical trials, modeling studies, and translational research aimed at advancing the future of HCV care.

Journey Maps

Presentations

11:00 AM - 11:15 AM
May 18 2026
Washington, D.C.

Ultra-Short Glecaprevir/Pibrentasvir Plus Ezetimibe Prevents Chronic HCV in HCV-Infected Recipients of HCV-Uninfected Non-Liver Transplants: 6-Year Outcomes of the Toronto Protocol

Andrea D Branch, PhD , Abstract Presenter
Hepatitis
11:15 AM - 11:30 AM
May 18 2026
Washington, D.C.

MDL-001 as a Next-Generation HCV Thumb-1 Inhibitor with Clinical-Stage Safety

Harrys A Torres, MD, FAASLD , Abstract Presenter
Hepatitis

Objectives

  • Describe emerging antiviral agents and combination regimens for Hepatitis C.
  • Discuss updates on long-term outcomes related to novel HCV therapies.
  • Identify predictive tools and post-cure interventions aimed at reducing long-term liver-related complications and advancing HCV-related cancer prevention.